



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/578,848	07/24/2006	Ulla Hellstrom	620-438	5041
23117 7590 03/18/2009 NIXON & VANDERHYE, PC 901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203				
EXAMINER				
KINSEY WHITE, NICOLE ERIN				
ART UNIT		PAPER NUMBER		
16-48				
MAIL DATE		DELIVERY MODE		
03/18/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/578,848

Applicant(s)

HELLSTROM ET AL.

Examiner

NICOLE KINSEY WHITE

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 December 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-12, 20 and 22 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-12, 20 and 22 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/S508)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Claim Objections

Claims 2 and 3 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claims, or amend the claims to place the claims in proper dependent form, or rewrite the claims in independent form.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, and 7-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Neurath et al. (EP 154902A).

The claims are directed to a method of predicting whether an individual having hepatitis B virus (HBV) infection will respond to interferon alpha (IFN- α) treatment; the method comprising;

determining the presence or absence of antibodies reactive with a preS1 peptide consisting of the sequence of residues 94-117 (SEQ ID NO:1) in a pre-treatment sample obtained from the individual, and;

predicting from the presence of said antibodies in said sample that said individual will respond to said treatment or predicting from the absence of said antibodies in said sample that said individual will not respond to said treatment.

The claimed method has one active step "determining the presence or absence of antibodies reactive with a preS1 peptide consisting of the sequence of residues 94-117 (SEQ ID NO:1) in a pre-treatment sample obtained from the individual." The preamble and the predicting step of the claim are not given patentable weight because these are mental processes resulting in no physical action or step. Once the presence or absence of antibodies is determined, no further active step is required by the claim. Therefore, the claim is interpreted as being directed to determining the presence or absence of antibodies in a sample.

Neurath et al. discloses a method for detecting the presence or absence of antibodies to pre-S of hepatitis B Virus in a sample, e.g., serum, comprising:

a) contacting the sample with a solid substrate coated with a non-labeled peptide containing an amino acid chain corresponding to at least six consecutive amino acids within the pre-S gene coded region of the envelope of HBV, the peptide free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus, incubating and washing said contacted sample;

b) contacting the incubated washed product obtained from step a above with a labeled peptide containing an amino acid chain corresponding to at least six consecutive amino acids within the pre-S gene coded region of the envelope of HBV,

Art Unit: 1648

said peptide free of an amino acid sequence corresponding to the naturally occurring envelope protein of hepatitis B virus, incubating and washing the resultant mass; and

c) determining the extent of labeled peptide present in the resultant mass obtained by step b above (see page 15, line 14 to page 17, line 4).

Neurath et al. also teaches preferred peptides of the invention, including SEQ ID NO:1 (see page 31, lines 24-25 and claim 25) which can be used in the method of Neurath et al.

Neurath et al. also discloses a process for the detection of antibodies to proteins coded for by the pre-S region of hepatitis B virus DNA, comprising the following steps:

(a) adsorbing on a solid substrate containing binding sites thereon, e.g., polystyrene beads, a peptide having an amino acid sequence corresponding to at least six consecutive amino acids within the pre-S gene coded region of the HBV envelope,

(b) contacting the substrate from step a with a material to saturate the binding sites thereon,

c) washing the substrate from step b,

d) contacting the substrate from step c with a specimen comprising human sera,

(e) incubating the resultant mass of step d,

(f) washing the resultant mass of step e,

(g) adding radiolabeled antibodies to human IgG or IgM to the resultant mass of step f to form a second resultant mass,

(h) subjecting the second resultant mass of step g to counting in a gamma counter,

- (i) subjecting normal sera utilized as a control to steps (a) to (h), and
- (j) comparing the counts of steps h and i.

In the above process for the detection of antibodies, ELISA techniques can be substituted for RIA techniques (see page 20, line 14 to page 21, line 13).

Claims 1-3, and 7-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Neurath et al. (EP 448126A).

Neurath et al. discloses a method for detecting the presence or absence of antibodies to pre-S of hepatitis B Virus in a test sample, e.g., serum (see page 8, lines 6-50 and page 9, lines 9-53).

Neurath et al. also discloses preferred peptides of the invention, including instant SEQ ID NO:1 (see page 13, lines 30-31) that can be used in the method.

The method of Neurath et al. for the detection of antibodies to proteins coded for by the pre-S region of hepatitis B virus DNA, comprising the following steps:

- (a) adsorbing on a solid substrate containing binding sites thereon, e.g., polystyrene beads, a peptide having an amino acid sequence corresponding to at least six consecutive amino acids within the pre-S gene coded region of the HBV envelope,
- (b) contacting the substrate from step a with a material to saturate the binding sites thereon,
- (c) washing the substrate from step b,
- (d) contacting the substrate from step c with a specimen comprising human sera,
- (e) incubating the resultant mass of step d,

Art Unit: 1648

- (f) washing the resultant mass of step e,
- (g) adding radiolabeled antibodies to human IgG or IgM to the resultant mass of step f to form a second resultant mass,
- (h) subjecting the second resultant mass of step g to counting in a gamma counter,
- (i) subjecting normal sera utilized as a control to steps (a) to (h), and
- (j) comparing the counts of steps h and i.

Claims 1-3 and 7-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Neurath et al. (U.S. Patent No. 4,847,080).

Neurath et al. discloses a method for the detection of antibodies to proteins coded for by the pre-S region of hepatitis B virus DNA. The method comprises:

- (a) adsorbing on a solid substrate containing binding sites thereon, e.g., polystyrene beads, a peptide having an amino acid sequence corresponding to at least six consecutive amino acids within the pre-S gene coded region of the HBV envelope,
- (b) contacting the substrate from step a with a material to saturate the binding sites thereon,
- (c) washing the substrate from step b,
- (d) contacting the substrate from step c with a specimen comprising human sera,
- (e) incubating the resultant mass of step d,
- (f) washing the resultant mass of step e,

(g) adding radiolabeled antibodies to human IgG or IgM to the resultant mass of step f to form a second resultant mass,

(h) subjecting the second resultant mass of step g to counting in a gamma counter,

(i) subjecting normal sera utilized as a control to steps (a) to (h), and

(j) comparing the counts of steps h and i.

In the above process for the detection of antibodies, ELISA techniques can be substituted for RIA techniques (col. 9, lines 3-31).

Neurath et al. also teaches preferred peptides of the invention, including SEQ ID NO:1 (col. 14, lines 8-10 and claim 22) that can be used in the method.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

Art Unit: 1648

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 4-6, 20 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Neurath et al. (EP 154902A), Neurath et al. (EP 448126A) or Neurath et al. (U.S. Patent No. 4,847,080) as applied to claim 1 above, and further in view of Zavaglia et al. (Italian Journal of Gastroenterology, 1996, 28(6):324-331, Abstract only).

The claims are directed to treating chronically infected individuals, treating individuals who are HBeAg positive or negative and treating HBV infected individuals with corticosteroid.

Neither Neurath et al. reference teaches the limitations of claims 4-6, 20 and 22. However, Zavaglia et al. teaches treating HBeAg+ individuals with interferon- α alone or in combination with the corticosteroid, deflazacort. Zavaglia et al. found that serum HBV DNA levels decreased significantly in both groups.

Therefore, it would have been obvious to one of ordinary skill in the art to modify the methods taught by Neurath et al. and administer interferon- α alone or in combination with a corticosteroid to treat individuals where antibodies against preS1 were detected, whether the individual was HBeAg positive or negative. One would have been motivated to do so and there would have been a reasonable expectation of success given the fact that it is well known in the art to treat HBV with interferon- α and given the suggestion by Zavaglia et al. that interferon- α alone or in conjunction with a corticosteroid significantly decreases serum HBV DNA levels.

Thus, the invention as a whole was clearly *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Response to Arguments

In the reply dated December 15, 2008, applicants argue that none of the cited references teach predicting the treatment outcome based on the presence or absence of preS1 antibodies. This argument has been fully considered, but not found persuasive.

As discussed above, the claimed method has one active step "determining the presence or absence of antibodies reactive with a preS1 peptide consisting of the sequence of residues 94-117 (SEQ ID NO:1) in a pre-treatment sample obtained from the individual." The preamble (predicting whether an individual having hepatitis B virus (HBV) infection will respond to interferon alpha (IFN α) treatment) and the predicting step of the claim are not given patentable weight because these are mental processes resulting in no physical action or step. Once the presence or absence of antibodies is determined, no further active step is required by the claim. Therefore, the claim is directed to determining the presence or absence of antibodies in a sample. Further, one of ordinary skill in the art cannot determine if the claimed method is being practiced because he/she cannot "see" the mental processes of the predicting step.

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **NICOLE KINSEY WHITE** whose telephone number is (571)272-9943. The examiner can normally be reached on Monday through Friday from 9:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campbell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Nicole Kinsey White/
Examiner, Art Unit 1648

/Stacy B Chen/
Primary Examiner, Art Unit 1648